D149 Dye_786643-20-7_DataSheet_MedChemExpress

Inhibitors, Agonists, Screening Libraries Data SheetBIOLOGICAL ACTIVITY:HSF1A is a cell–permeable activator of heat shock transcription factor 1 (HSF1).IC50 & Target: HSF1[1]In Vitro: HSF1A protects cells from stress–induced apoptosis, binds TRiC subunits and inhibits TRiC activity without perturbation of ATP hydrolysis. Genetic inactivation or depletion of the TRiC complex results in human HSF1 activation and HSF1A inhibits the direct interaction between purified TRiC and HSF1 in vitro. Moreover, fluorescence anisotropy experiments using FITC coupled to HSF1A demonstrates that HSF1A–FITC binds to a purified Tcp1 subunit of TRiC with an affinity of approximately 600 nM. This is validated qualitatively via titration of purified Tcp1 into binding reactions containing 500 nM Biotin or HSF1A–Biotin [1]. Quantification bycounting the number of cell containing aggregates as a function of the total number of cells reveals that at HSF1A concentrations as low as 2 μM, a reduced number of aggregate–containing cells are observed. The fraction of cells containing aggregates continued to decrease in a dose–dependent manner such that pretreatment with 12 μM HSF1A resulta in ~20% of the cells exhibiting aggregates visible by fluorescence microscopy [2].In Vivo: HSF1A enhances HSF1 activity, stabilizes HSF1 expression and minimizes Doxorubicin (DOX)–induced cardiac damage. WKY rats are challenged with DOX (accumulated dose: 30 mg/kgw), and DOX combined with HSF1A (100 mg/kgw/day). Supplementation with HSF1A significantly elevates cardiac functions back to the levels of the control group. HSF1A has been shown to stimulate human HSF1 nuclear translocation, elevate protein chaperone expression and ameliorate protein misfolding and cell death in aneurodegenerative disease model. The echocardiographic results show that HSF1A also alleviates DOX–induced failures in cardiac function [3].PROTOCOL (Extracted from published papers and Only for reference)Kinase Assay:[1]Protein extracts are generated from mammalian, yeast and E. coli cultures using biotin–binding buffer (20 mM HEPES,5 mM MgCl 2, 1 mM EDTA, 100 mM KCl, 0.03% NP–40) supplemented with 1% Trition–X100 and protease inhibitors. Approximately 0.5mg of protein extract is incubated with 100 μM HSF1A–Biotin for 4 h at 4°C and HSF1A–Biotin associated proteins captured by with NeutrAvidin Agarose Resin. After washing in biotin binding buffer proteins are eluted using 50 μL biotin elution buffer (100 mM Tris,150 mM NaCl, 0.1 mM EDTA, 2 mM D–biotin), resolved on a 4–20% SDS–PAGE, and immunoblotted. For purified TRiC and Hsp70analyses, 5 nM protein is incubated in biotin–binding buffer+0.5% Triton X–100 with 100 μM biotin or 100 μM HSF1A–Biotin for 4 h at 4°C and captured with NeutrAvidin Resin. For NiNTA purified yeast Tcp1, different concentrations of Tcp1 0.5 μM, 1 mM, 2 mM, 3 mM and 4 mM in 25 mM Hepes pH 7.5, 150 mM NaCl are incubated with 0.5 μM Biotin or HSF1A–Biotin for 4 h at 4°C and captured with NeutrAvidin Resin [1].Cell Assay:[2]PC12 cells seeded into a 96–well plate (5×104 cells/well) are treated with increasing concentrations of HSF1A (2, 4, 8 andProduct Name:HSF1A Cat. No.:HY-103000CAS No.:1196723-93-9Molecular Formula:C21H19N3O2S2Molecular Weight:409.52Target:HSP Pathway:Cell Cycle/DNA Damage; Metabolic Enzyme/Protease Solubility:DMSO: ≥ 150 mg/mL12 μM) for 15 h, at which time httQ74–GFP expression is stimulated by incubation in the presence of 1 μg/mL Doxycycline for 5 d. Cell viability is assessed via the XTT viability assay[2].Animal Administration:[3]Rat[3]Ten–week–old Wistar Kyoto rats (WKY) are used. The rats are housed at a constant temperature (22°C) on a 12–h light/dark cycle with food and tap water. The animals are arranged into three groups: WKY rats (the control group), DOX rats and DOX rats treated with HSF1A. Each group contain five animals. The DOX group is injected with DOX (5 mg/kg) for 6 consecutive weeks intraperitoneal injection to achieve a cumulative dose of 30 mg/kg, which has been well documented to achieve cardiotoxicity. The small molecular HSF1 activator HSF1A (100 mg/kg/day) is injected intraperitoneally.References:[1]. Neef DW, et al. A direct regulatory interaction between chaperonin TRiC and stress–responsive transcription factor HSF1. Cell Rep. 2014 Nov 6;9(3):955–66.[2]. Neef DW, et al. Modulation of heat shock transcription factor 1 as a therapeutic target for small molecule intervention in neurodegenerative disease. PLoS Biol. 2010 Jan 19;8(1):e1000291.[3]. Huang CY, et al. Doxorubicin attenuates CHIP–guarded HSF1 nuclear translocation and protein stability to trigger IGF–IIR–dependent cardiomyocyte death. Cell Death Dis. 2016 Nov 3;7(11):e2455.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。

碧云天生物技术/Beyotime Biotechnology订货热线：400-168-3301或800-8283301订货e-mail：******************技术咨询：*****************网址：碧云天网站微信公众号Cyclodextrin Glucanotransferase (Crude Enzyme)产品编号产品名称包装P3618-100ml Cyclodextrin Glucanotransferase (Crude Enzyme) 100mlP3618-1L Cyclodextrin Glucanotransferase (Crude Enzyme) 1L产品简介：Cyclodextrin Glucanotransferase，中文名为环糊精糖基转移酶，催化淀粉转移葡萄糖基生成环糊精。

本产品为大肠杆菌表达的环糊精糖基转移酶，并经简单纯化获得的可以确保达到一定酶活力的粗酶液。

由于本产品需新鲜制备，确认订购后约6个工作日才可以发货。

个别情况首次制备出现问题，发货时间会顺延。

本产品可以提供十公斤、百公斤乃至吨级的粗酶液，如有需求请联系碧云天。

In enzymology, a cyclomaltodextrin glucanotransferase is an enzyme that catalyzes the chemical reaction of cyclizing part of a 1,4-alpha-D-glucan molecule through the formation of a 1,4-alpha-D-glucosidic bond.This enzyme belongs to the family of glycosyltransferases, specifically the hexosyltransferases.This product with the indicated enzyme activity was briefly purified from engineered E.coli.产品详细信息见下表：About this productName Cyclodextrin Glucanotransferase (Crude Enzyme)；环糊精糖基转移酶(粗酶液)Application 催化淀粉转移葡萄糖基生成环糊精Appearance Clear to translucent yellow solutionEnzyme activity UndeterminedAbout this enzymeName Cyclodextrin Glucanotransferase；环糊精糖基转移酶CAS Number 9030-09-5EC Number 2.4.1.19Enzymatic Reaction Cyclizes part of a (1→4)-α-D-glucan chain by formation of a (1→4)-α-D-glucosidic bondSynonyms Bacillus macerans amylase; cyclodextrin glucanotransferase; α-cyclodextrin glucanotransferase; α-cyclodextrin glycosyltransferase; β-cyclodextrin glucanotransferase; β-cyclodextrin glycosyltransferase; γ-cyclodextrin glycosyltransferase; cyclodextrin glycosyltransferase; cyclomaltodextrin glucotransferase; cyclomaltodextrin glycosyltransferase; konchizaimu; α-1,4-glucan 4-glycosyltransferase, cyclizing; BMA; CGTase; neutral-cyclodextrin glycosyltransferase; 1,4-α-D-glucan 4-α-D-(1,4-α-D-glucano)-transferase (cyclizing)Systematic name (1→4)-α-D-glucan:(1→4)-α-D-glucan 4-α-D-[(1→4)-α-D-glucano]-transferase (cyclizing)Cofactor(s) -Application industry; synthesis; nutrition; pharmacology包装清单：产品编号产品名称包装P3618-100ml Cyclodextrin Glucanotransferase (Crude Enzyme) 100mlP3618-1L Cyclodextrin Glucanotransferase (Crude Enzyme) 1L－说明书1份保存条件：-20ºC或更低温度保存，至少1个月有效。

第43 卷第 2 期2024 年2 月Vol.43 No.2285~291分析测试学报FENXI CESHI XUEBAO（Journal of Instrumental Analysis）超高效液相色谱-三重四极杆质谱法测定化妆品中8种替丁类禁用药物张秋炎，梁维维，罗辉泰*，廖均涛，黄芳，吴惠勤（广东省科学院测试分析研究所（中国广州分析测试中心），广东省化学测量与应急检测技术重点实验室，广东省中药质量安全工程技术研究中心，广东广州510070）摘要：建立了同时测定5种不同基质类型化妆品中8种替丁类药物的超高效液相色谱-三重四极杆质谱法（UHPLC-MS/MS）。

不同基质类型化妆品样品经水-乙腈（2∶8，体积比）涡旋混匀、超声提取后过滤上机分析。

选用YMC-Triart C18色谱柱（100 mm×2.1 mm，3.0 μm），以0.2%甲酸溶液-乙腈为流动相进行梯度洗脱分离，质谱分析采用电喷雾正离子模式和多反应监测模式。

实验表明，8种替丁类药物在各自质量浓度范围内线性关系良好，相关系数（r2）为0.997 5~0.998 6，检出限为0.06~0.3 μg/L，定量下限为0.2~1.0 μg/L。

在3个不同加标水平下，水剂类、膏霜类、乳液类、凝胶类和粉剂类样品的平均回收率分别为80.7%~106%、90.1%~102%、82.6%~101%、82.0%~110%和86.6%~101%；相对标准偏差为0.70%~7.9%。

该法前处理过程简单高效，易操作，灵敏度高，适用于上述5种类型化妆品中8种替丁类药物的同时快速定性定量分析。

关键词：超高效液相色谱-三重四极杆质谱法；化妆品；抗组胺；替丁类药物中图分类号：O657.7；TQ658文献标识码：A 文章编号：1004-4957（2024）02-0285-07Determination of 8 Prohibited Tidine Drugs in Cosmetics by UltraHigh Performance Liquid Chromatography-Triple QuadrupoleMass SpectrometryZHANG Qiu-yan，LIANG Wei-wei，LUO Hui-tai*，LIAO Jun-tao，HUANG Fang，WU Hui-qin（Guangdong Provincial Engineering Research Center for Quality and Safety of Traditional Chinese Medicine，Guangdong Provincial Key Laboratory of Chemical Measurement and Emergency Test Technology，Institute of Analysis，Guangdong Academy of Sciences（China National Analytical Center，Guangzhou），Guangzhou　510070，China）Abstract：A new method for the simultaneous and rapid determination of 8 tidine drugs in 5 different matrix types of cosmetics by ultra high performance liquid chromatography-triple quadrupole mass spectrometry（UHPLC-MS/MS） was established. The different matrix cosmetic samples were dipersed with water-acetonitrile（2∶8，volume ratio） and ultrasonic extraction，and the filtrate was analyzed by UHPLC-MS/MS. A YMC-Triart C18 column（100 mm×2.1 mm，3.0 μm） was used as separation chromatographic column，with 0.2% formic acid aqueous solution and acetonitrile as mobile phases under gradient elution. Eight tidines drugs were analyzed in the positive mode using multiple reaction monitoring mode and electrospray ionization mass spectrometry. The results showed that the correla⁃tion coefficients for linear calibration curves were ranged of 0.997 5-0.998 6 in the corresponding concentration range. The limits of detection（LODs） of 8 tidine drugs were in the range of 0.06-0.3 μg/L，and the limits of quantitation（LOQs） were in the range of 0.2-1.0 μg/L. The average recover⁃ies of 8 tidine drugs from water aqua，cream，lotion，gel and powder samples at three different spiked levels ranged of 80.7%-106%，90.1%-102%，82.6%-101%，82.0%-110% and 86.6%-101%，re⁃spectively，with relative standard deviations ranged of 0.70%-7.9%. The established method is sim⁃ple，effective，easy to operate，high sensitive，and accurate，and is suitable for the determination of 8 tidine drugs in 5 different matrixes of cosmetics（including water aqua，cream，lotion，gel and收稿日期：2023－08－14；修回日期：2023－10－04基金项目：广东省科学院打造综合产业技术创新中心行动资金项目“高端医疗健康与高效生物转化关键技术研究及应用”（2022GDASZH-2022010110）∗通讯作者：罗辉泰，副研究员，研究方向：色谱-质谱分析技术应用，E-mail：luohuitai@doi：10.12452/j.fxcsxb.23081401第 43 卷分析测试学报powder samples ）.Key words ：UHPLC-MS/MS ；cosmetics ；antihistamine ；tidine drugs化妆品产业高质量发展的同时，其安全问题也日益引起消费者的重视。

粉防己碱的药理作用及临床应用研究进展孔晓旭1，2，左红艳1*，李杨1，2*［摘要］粉防己碱（tetrandrine，TET）是从防己科植物防己中提取出的一种双苄基异喹啉生物碱。

目前研究发现，TET作为粉防己植物中的重要活性成分之一，药理作用也较为广泛。

TET主要作用于机体的循环系统、呼吸系统及运动系统，具有抗肿瘤、抗心律失常、抗高血压、抗炎、抗硅肺及抗纤维化等多种药理作用，因此在临床上具有较高的应用价值。

本文就TET的药理作用机制、临床剂型及应用等方面的研究成果进行综述，以期为后续相关研究开展提供参考。

［关键词］粉防己碱；钙离子通道阻滞剂；药理作用；剂型；机制［中图分类号］R96；R285［文献标志码］A［文章编号］1674-0440（2020）07-0496-06 DOI：10.13220/ki.jipr.2020.07.002Pharmacological effects and clinical application of tetrandrine：research advancesKONG Xiao-xu1，2，ZUO Hong-yan1*，LI Yang1，2*（1.Institute of Radiation Medcine，Academy of Military Medical Sciences，Academy of Military Sciences，Beijing100850，China；2.Anhui Medical University，Hefei230032，China）［Abstract］Tetrandrine（TET）is a bisbenzyl isoquinoline alkaloid extracted from the plant Stephania tetrandra.TET is one of the important active ingredients of S.tetrandra，showing pharmacological effects mainly on the circulatory，respiratory and locomotor systems，such as the anti-inflammatory，anti-tumor，anti-arrhythmia，anti-hypertensive，anti-silicosis and fibrosis effect，and thus has a high clinical application value.This article reviews research achievements of the pharmacological effects，action mechanisms，dosage forms and clinical applications of TET，in order to provide reference for related research.［Key word］tetrandrine；calcium channel blocker；pharmacological action；dosage form；mechanism防己，又名汉防己、粉防己，是一种常用传统中药，主要产于中国浙江、广东、广西、福建等地。

EUROPEAN COMMISSIONDG Internal Market, Industry, Entrepreneurship and SMEsConsumer, Environmental and Health TechnologiesHealth technology and Cosmetics备注：中文翻译中的临床调查=临床研究，评估=评价、设备=器械、数据=资料MEDDEV 2.7/1 revision 4June 2016GUIDELINES ON MEDICAL DEVICES 医疗器械指南CLINICAL EVALUATION:A GUIDE FOR MANUFACTURERS AND NOTIFIED BODIES UNDER DIRECTIVES 93/42/EEC and 90/385/EECNoteThe present Guidelines are part of a set of Guidelines relating to questions of application of EC-Directives on medical Devices. They are legally not binding. The Guidelines have been carefully drafted through a process of intensive consultation of the various interested parties (competent authorities, Commission services, industries, other interested parties) during which intermediate drafts where circulated and comments were taken up in the document. Therefore, this document reflects positions taken by representatives of interest parties in the medical devices sector. These guidelines incorporate changes introduced by Directive 2007/47/EC amending Council Directive 90/385/EEC and Council Directive93/42/EEC.本指南为一系列与CE—医疗器械指令应用问题相关的指南中的一部分。

硫酸皮肤素差向异构酶(DSE)ELISA试剂盒说明书本试剂仅供研究使用标本：体液硫酸皮肤素差向异构酶(DSE)ELISA试剂盒说明书试验原理：BFGF试剂盒是固相夹心法酶联免疫吸附实验（ELISA）.已知BFGF浓度的标准品、未知浓度的样品加入微孔酶标板内进行检测。

先将BFGF和生物素标记的抗体同时温育。

人碱性成纤维细胞生长因子ELISA 检测试剂盒洗涤后，加入亲和素标记过的HRP。

再经过温育和洗涤，去除未结合的酶结合物，然后加入底物A、B，和酶结合物同时作用。

产生颜色。

颜色的深浅和样品中BFGF的浓度呈比例关系。

硫酸皮肤素差向异构酶(DSE)ELISA试剂盒说明书自备材料1．蒸馏水。

2．加样器：5ul、10ul、50ul、100ul、200、500ul、1000ul。

3．振荡器及磁力搅拌器等。

安全性1．避免直接接触终止液和底物A、B。

一旦接触到这些液体，请尽快用水冲洗。

2．实验中不要吃喝、抽烟或使用化妆品。

3．不要用嘴吸取试剂盒里的任何成份。

硫酸皮肤素差向异构酶(DSE)ELISA试剂盒说明书操作注意事项1．试剂应按标签储存，使用前恢复到室温。

稀稀过后的标准品应丢弃，不可保存。

2．实验中不用的板条应立即放回包装袋中，密封保存，以免变质。

3．不用的其它试剂应包装好或盖好。

不同批号的试剂不要混用。

保质前使用。

4．使用一次性的吸头以免交叉污染，吸取终止液和底物A、B液时，避免使用带金属部分的加样器。

5．使用干净的塑料容器配置洗涤液。

使用前充分混匀试剂盒里的各种成份及样品。

6．洗涤酶标板时应充分拍干，不要将吸水纸直接放入酶标反应孔中吸水。

7．底物A应挥发，避免长时间打开盖子。

底物B对光敏感，避免长时间暴露于光下。

避免用手接触，有毒。

实验完成后应立即读取OD值。

8．加入试剂的顺序应一致，以保证所有反应板孔温育的时间一样。

9．按照中标明的时间、加液的量及顺序进行温育操作。

硫酸皮肤素差向异构酶(DSE)ELISA试剂盒说明书样品收集、处理及保存方法1、血清-----操作过程中避免任何细胞刺激。

呋喃妥因代谢物（AHD）ELISA检测试剂盒说明书一、概要用来检测呋喃妥因代谢物的最常用方法是LC-UV，LC-MS和LC-MS/MS。

酶联免疫方法结合了色谱技术，采用AHD衍生物的特异性抗体，具有很高的精确度和灵敏度，较低的操作技术要求和短暂的检测时间，检测样本量大等特点在检测中很好的表现出来。

二、试验原理本试剂盒采用间接竞争ELISA方法，在酶标板微孔条上预包被偶联抗原，样本中的残留物的AHD经衍生化后和微孔条上预包被的偶联抗原竞争抗呋喃妥因代谢物的衍生物抗体，加入酶标二抗后，用TMB底物显色，样本吸光值与其所含残留物AHD代谢物的含量成负相关，与标准曲线比较即可得出样本中呋喃妥因代谢物的残留量。

三、适用范围可定性、定量检测动物组织（鸡、猪、牛、鱼、虾等）、牛奶和蜂蜜中呋喃妥因代谢物的残留量。

四、交叉反应率呋喃妥因代谢物…………………………………………100%呋喃唑酮代谢物…………………………………小于0.1%呋喃它酮代谢物…………………………………小于0.1%硝基糠腙（呋喃西林）代谢物…………………小于0.1%呋喃唑酮………………………………………………小于1%呋喃它酮………………………………………………小于1%呋喃妥因………………………………………………13%呋喃西林…………………………………………小于1%五、使用单位需自备的设备及试剂设备：┅┅微孔板酶标仪450nm/630nm┅┅旋转蒸发仪/氮气吹干装置┅┅均质器┅┅振荡器┅┅涡旋仪┅┅离心机┅┅天平：感量0.01g┅┅刻度移液管：10ml┅┅洗耳球┅┅容量瓶：100ml、1L┅┅玻璃试管：10ml┅┅聚苯乙烯离心管：50ml┅┅微量移液器：单道 20ml～200ml、100ml～1000ml 多道 250ml试剂：┅┅乙酸乙酯(分析纯)┅┅正己烷（或正庚烷）(分析纯)┅┅三水合磷酸氢二钾(分析纯)┅┅甲醇(分析纯)┅┅二水合亚硝基铁氰化钠（Na2Fe(CN)5·NO·2H2O）（分析纯）（供奶样用）┅┅七水合硫酸锌(ZnSO4·7 H2O) (分析纯)（供奶样用）┅┅浓盐酸┅┅氢氧化钠(分析纯)┅┅去离子水六、提供的材料与试剂1、96孔酶标板×1块（包被有偶联抗原）2、标准液×6瓶：（1ml/瓶）0ppb，0.1ppb，0.3ppb，0.9ppb，2.7ppb，8.1ppb3、高浓度标准品：（1ml/瓶） 100ppb4、酶标二抗12ml …………………… 红色帽5、抗体工作液7ml …………………… 绿色帽6、底物液 A 液7ml …………………… 白色帽7、底物液 B 液7ml …………………… 红色帽8、终止液7ml …………………… 黄色帽9、20×浓缩洗涤液40ml……………………… 透明帽10、2×浓缩复溶液 50ml……………………… 蓝色帽11、2-硝基苯甲醛15.1mg…………………… 黑色帽七、溶液的配制配液1: 衍生化试剂向装有2-硝基苯甲醛的试剂瓶中加甲醇溶解定容至10ml（浓度为10mM）。

Inhibitors, Agonists, Screening LibrariesSafety Data Sheet Revision Date:Aug.-08-2017Print Date:Aug.-08-20171. PRODUCT AND COMPANY IDENTIFICATION1.1 Product identifierProduct name :D8-MMAECatalog No. :HY-15162ACAS No. :2070009-72-01.2 Relevant identified uses of the substance or mixture and uses advised againstIdentified uses :Laboratory chemicals, manufacture of substances.1.3 Details of the supplier of the safety data sheetCompany:MedChemExpress USATel:609-228-6898Fax:609-228-5909E-mail:sales@1.4 Emergency telephone numberEmergency Phone #:609-228-68982. HAZARDS IDENTIFICATION2.1 Classification of the substance or mixtureNot a hazardous substance or mixture.2.2 GHS Label elements, including precautionary statementsNot a hazardous substance or mixture.2.3 Other hazardsNone.3. COMPOSITION/INFORMATION ON INGREDIENTS3.1 SubstancesSynonyms:D8–Monomethyl auristatin E; D8–Vedotin; D8 MMAEFormula:C39H59D8N5O7Molecular Weight:726.03CAS No. :2070009-72-04. FIRST AID MEASURES4.1 Description of first aid measuresEye contactRemove any contact lenses, locate eye-wash station, and flush eyes immediately with large amounts of water. Separate eyelids with fingers to ensure adequate flushing. Promptly call a physician.Skin contactRinse skin thoroughly with large amounts of water. Remove contaminated clothing and shoes and call a physician.InhalationImmediately relocate self or casualty to fresh air. If breathing is difficult, give cardiopulmonary resuscitation (CPR). Avoid mouth-to-mouth resuscitation.IngestionWash out mouth with water; Do NOT induce vomiting; call a physician.4.2 Most important symptoms and effects, both acute and delayedThe most important known symptoms and effects are described in the labelling (see section 2.2).4.3 Indication of any immediate medical attention and special treatment neededTreat symptomatically.5. FIRE FIGHTING MEASURES5.1 Extinguishing mediaSuitable extinguishing mediaUse water spray, dry chemical, foam, and carbon dioxide fire extinguisher.5.2 Special hazards arising from the substance or mixtureDuring combustion, may emit irritant fumes.5.3 Advice for firefightersWear self-contained breathing apparatus and protective clothing.6. ACCIDENTAL RELEASE MEASURES6.1 Personal precautions, protective equipment and emergency proceduresUse full personal protective equipment. Avoid breathing vapors, mist, dust or gas. Ensure adequate ventilation. Evacuate personnel to safe areas.Refer to protective measures listed in sections 8.6.2 Environmental precautionsTry to prevent further leakage or spillage. Keep the product away from drains or water courses.6.3 Methods and materials for containment and cleaning upAbsorb solutions with finely-powdered liquid-binding material (diatomite, universal binders); Decontaminate surfaces and equipment by scrubbing with alcohol; Dispose of contaminated material according to Section 13.7. HANDLING AND STORAGE7.1 Precautions for safe handlingAvoid inhalation, contact with eyes and skin. Avoid dust and aerosol formation. Use only in areas with appropriate exhaust ventilation.7.2 Conditions for safe storage, including any incompatibilitiesKeep container tightly sealed in cool, well-ventilated area. Keep away from direct sunlight and sources of ignition.Recommended storage temperature: 4°C, stored under nitrogenShipping at room temperature if less than 2 weeks.7.3 Specific end use(s)No data available.8. EXPOSURE CONTROLS/PERSONAL PROTECTION8.1 Control parametersComponents with workplace control parametersThis product contains no substances with occupational exposure limit values.8.2 Exposure controlsEngineering controlsEnsure adequate ventilation. Provide accessible safety shower and eye wash station.Personal protective equipmentEye protection Safety goggles with side-shields.Hand protection Protective gloves.Skin and body protection Impervious clothing.Respiratory protection Suitable respirator.Environmental exposure controls Keep the product away from drains, water courses or the soil. Cleanspillages in a safe way as soon as possible.9. PHYSICAL AND CHEMICAL PROPERTIES9.1 Information on basic physical and chemical propertiesAppearance White to off-white (Solid)Odor No data availableOdor threshold No data availablepH No data availableMelting/freezing point No data availableBoiling point/range No data availableFlash point No data availableEvaporation rate No data availableFlammability (solid, gas)No data availableUpper/lower flammability or explosive limits No data availableVapor pressure No data availableVapor density No data availableRelative density No data availableWater Solubility No data availablePartition coefficient No data availableAuto-ignition temperature No data availableDecomposition temperature No data availableViscosity No data availableExplosive properties No data availableOxidizing properties No data available9.2 Other safety informationNo data available.10. STABILITY AND REACTIVITY10.1 ReactivityNo data available.10.2 Chemical stabilityStable under recommended storage conditions.10.3 Possibility of hazardous reactionsNo data available.10.4 Conditions to avoidNo data available.10.5 Incompatible materialsStrong acids/alkalis, strong oxidising/reducing agents.10.6 Hazardous decomposition productsUnder fire conditions, may decompose and emit toxic fumes.Other decomposition products - no data available.11.TOXICOLOGICAL INFORMATION11.1 Information on toxicological effectsAcute toxicityClassified based on available data. For more details, see section 2Skin corrosion/irritationClassified based on available data. For more details, see section 2Serious eye damage/irritationClassified based on available data. For more details, see section 2Respiratory or skin sensitizationClassified based on available data. For more details, see section 2Germ cell mutagenicityClassified based on available data. For more details, see section 2CarcinogenicityIARC: No component of this product present at a level equal to or greater than 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.ACGIH: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by ACGIH.NTP: No component of this product present at a level equal to or greater than 0.1% is identified as a anticipated or confirmed carcinogen by NTP.OSHA: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by OSHA.Reproductive toxicityClassified based on available data. For more details, see section 2Specific target organ toxicity - single exposureClassified based on available data. For more details, see section 2Specific target organ toxicity - repeated exposureClassified based on available data. For more details, see section 2Aspiration hazardClassified based on available data. For more details, see section 212. ECOLOGICAL INFORMATION12.1 ToxicityNo data available.12.2 Persistence and degradabilityNo data available.12.3 Bioaccumlative potentialNo data available.12.4 Mobility in soilNo data available.12.5 Results of PBT and vPvB assessmentPBT/vPvB assessment unavailable as chemical safety assessment not required or not conducted.12.6 Other adverse effectsNo data available.13. DISPOSAL CONSIDERATIONS13.1 Waste treatment methodsProductDispose substance in accordance with prevailing country, federal, state and local regulations.Contaminated packagingConduct recycling or disposal in accordance with prevailing country, federal, state and local regulations.14. TRANSPORT INFORMATIONDOT (US)This substance is considered to be non-hazardous for transport.IMDGThis substance is considered to be non-hazardous for transport.IATAThis substance is considered to be non-hazardous for transport.15. REGULATORY INFORMATIONSARA 302 Components:No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.SARA 313 Components:This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.SARA 311/312 Hazards:No SARA Hazards.Massachusetts Right To Know Components:No components are subject to the Massachusetts Right to Know Act.Pennsylvania Right To Know Components:No components are subject to the Pennsylvania Right to Know Act.New Jersey Right To Know Components:No components are subject to the New Jersey Right to Know Act.California Prop. 65 Components:This product does not contain any chemicals known to State of California to cause cancer, birth defects, or anyother reproductive harm.16. OTHER INFORMATIONCopyright 2017 MedChemExpress. The above information is correct to the best of our present knowledge but does not purport to be all inclusive and should be used only as a guide. The product is for research use only and for experienced personnel. It must only be handled by suitably qualified experienced scientists in appropriately equipped and authorized facilities. The burden of safe use of this material rests entirely with the user. MedChemExpress disclaims all liability for any damage resulting from handling or from contact with this product.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。

第３４卷第４期化㊀学㊀研㊀究Ｖｏｌ．３４㊀Ｎｏ．４２０２３年７月ＣＨＥＭＩＣＡＬ㊀ＲＥＳＥＡＲＣＨＪｕｌ．２０２３采用超高效液相色谱⁃四极杆⁃静电场轨道阱高分辨质谱快速鉴定板蓝根的化学成分崔维恒，邓晓兰∗，王思琴（中南大学湘雅医学院附属海口医院（海口市人民医院）药学部，海南海口５７０２０８）收稿日期：２０２２⁃０４⁃１９基金项目：海南省自然科学基金（２０Ａ２００３９）作者简介：崔维恒（１９８９－），女，主管药师，研究方向：医院临床药学㊂∗通信作者，Ｅ⁃ｍａｉｌ：ｄｘｌ１２２０＠１６３．ｃｏｍ摘㊀要：采用超高效液相色谱⁃四极杆⁃静电场轨道阱高分辨质谱（ＵＰＬＣ⁃Ｑ⁃Ｅｘａｃｔｉｖｅ⁃ｏｒｂｉｔｒａｐＭＳ）对板蓝根７０％乙醇提取物中的化学成分进行快速鉴定㊂色谱柱：ＨｙｐｅｒｓｉｌＧＯＬＤａＱ色谱柱（１００ｍｍˑ２．１ｍｍ，１．９μｍ）㊂流动相：含０．１％甲酸的水溶液（Ａ液）和含０．１％甲酸的乙腈（Ｂ液）㊂采用以下梯度进行洗脱：０ ２ｍｉｎ５％Ｂ液；２ ２２ｍｉｎ５％ ９５％Ｂ液；２２ ２７ｍｉｎ９５％Ｂ液；２７ ３０ｍｉｎ５％Ｂ液㊂流速为０．３ｍＬ／ｍｉｎ，柱温４０ħ，进样量为５μＬ㊂结果显示从板蓝根中鉴定１１１个化合物，包括１２个氨基酸类㊁１２个苯丙素类㊁２个酚类㊁６个核苷类㊁５个黄酮类㊁１１个生物碱类㊁４个糖类㊁４个萜类㊁７个酰胺类㊁４个香豆素类㊁３３个有机酸类㊁１个甾体类和１０个其他类㊂本研究对板蓝根的化学成分进行了快速鉴定，为进一步研究板蓝根的药效物质基础和资源利用提供参考㊂关键词：板蓝根；化学成分；高分辨质谱中图分类号：Ｏ６５６文献标志码：Ａ文章编号：１００８－１０１１（２０２３）０４－０３１３－０６ＲａｐｉｄｉｄｅｎｔｉｆｉｃａｔｉｏｎｏｆｃｈｅｍｉｃａｌｃｏｎｓｔｉｔｕｅｎｔｓｉｎＩｓａｔｉｄｉｓＲａｄｉｘｂａｓｅｄｏｎＵＰＬＣ⁃Ｑ⁃Ｅｘａｃｔｉｖｅ⁃ＯｒｂｉｔｒａｐＭＳＣＵＩＷｅｉｈｅｎｇ ＤＥＮＧＸｉａｏｌａｎ∗ ＷＡＮＧＳｉｑｉｎＤｅｐａｒｔｍｅｎｔｏｆＰｈａｒｍａｃｙ ＴｈｅＡｆｆｉｌｉａｔｅｄＨａｉｋｏｕＨｏｓｐｉｔａｌｏｆＸｉａｎｇｙａＭｅｄｉｃａｌＣｏｌｌｅｇｅｏｆＣｅｎｔｒａｌＳｏｕｔｈＵｎｉｖｅｒｓｉｔｙＨａｉｋｏｕＰｅｏｐｌｅ ｓＨｏｓｐｉｔａｌ Ｈａｉｋｏｕ５７０２０８ Ｈａｉｎａｎ ＣｈｉｎａＡｂｓｔｒａｃｔ Ｕｌｔｒａ⁃ｈｉｇｈｐｅｒｆｏｒｍａｎｃｅｌｉｑｕｉｄｃｈｒｏｍａｔｏｇｒａｐｈｙｔａｎｄｅｍｈｙｂｒｉｄｑｕａｄｒｕｐｏｌｅｏｒｂｉｔｒａｐｍａｓｓｓｐｅｃｔｒｏｍｅｔｒｙ（ＵＰＬＣ⁃Ｑ⁃Ｅｘａｃｔｉｖｅ⁃ｏｒｂｉｔｒａｐＭＳ）ｗａｓｕｓｅｄｔｏｒａｐｉｄｌｙｉｄｅｎｔｉｆｙｔｈｅｃｈｅｍｉｃａｌｃｏｎｓｔｉｔｕｅｎｔｓｉｎ７０％ｅｔｈａｎｏｌｅｘｔｒａｃｔｏｆＩｓａｔｉｄｉｓＲａｄｉｘ．ＴｈｅｔｙｐｅｏｆｃｏｌｕｍｎｗａｓＨｙｐｅｒｓｉｌＧＯＬＤａＱｃｏｌｕｍｎ（１００ｍｍˑ２．１ｍｍ，１．９μｍ）．Ｔｈｅｍｏｂｉｌｅｐｈａｓｅｓｗｅｒｅ０．１％ｆｏｒｍｉｃａｃｉｄ⁃ｗａｔｅｒ（ｌｉｑｕｉｄＡ）ａｎｄ０．１％ｆｏｒｍｉｃａｃｉｄ⁃ａｃｅｔｏｎｉｔｒｉｌｅ（ｌｉｑｕｉｄＢ）ｗｉｔｈｔｈｅｅｌｕｔｉｏｎｇｒａｄｉｅｎｔｏｆ０－２ｍｉｎ５％Ｂ；２－２２ｍｉｎ５％－９５％Ｂ；２２－２７ｍｉｎ９５％Ｂ；２７－３０ｍｉｎ５％Ｂ．Ｔｈｅｆｌｏｗｒａｔｅｗａｓ０．３ｍＬ／ｍｉｎ，ｔｈｅｃｏｌｕｍｎｔｅｍｐｅｒａｔｕｒｅｗａｓ４０ħ，ａｎｄｔｈｅｉｎｊｅｃｔｉｏｎｖｏｌｕｍｅｗａｓ５μＬ．Ｔｈｅｒｅｓｕｌｔｓｓｈｏｗｔｈａｔ１１１ｃｏｍｐｏｕｎｄｓａｒｅｉｄｅｎｔｉｆｉｅｄｆｒｏｍＩｓａｔｉｄｉｓＲａｄｉｘ，ｉｎｃｌｕｄｉｎｇ１２ａｍｉｎｏａｃｉｄｓ，１２ｐｈｅｎｙｌｐｒｏｐａｎｏｉｄｓ，２ｐｈｅｎｏｌｓ，６ｎｕｃｌｅｏｓｉｄｅｓ，５ｆｌａｖｏｎｏｉｄｓ，１１ａｌｋａｌｏｉｄｓ，４ｃａｒｂｏｈｙｄｒａｔｅｓ，４ｔｅｒｐｅｎｏｉｄｓ，７ａｍｉｄｅｓ，４ｃｏｕｍａｒｉｎｓ，３３ｏｒｇａｎｉｃａｃｉｄｓ，１ｓｔｅｒｏｉｄａｎｄ１０ｏｔｈｅｒｓ．ＴｈｅｃｈｅｍｉｃａｌｃｏｎｓｔｉｔｕｅｎｔｓｉｎＩｓａｔｉｄｉｓＲａｄｉｘｗｅｒｅｉｄｅｎｔｉｆｉｅｄｉｎｔｈｉｓｓｔｕｄｙ．ＩｔｐｒｏｖｉｄｅｓａｂａｓｉｓｆｏｒｆｕｒｔｈｅｒｓｔｕｄｙｏｎｔｈｅｐｈａｒｍａｃｏｄｙｎａｍｉｃｓｕｂｓｔａｎｃｅｂａｓｉｓａｎｄｒｅｓｏｕｒｃｅｕｔｉｌｉｚａｔｉｏｎｏｆＩｓａｔｉｄｉｓＲａｄｉｘ．Ｋｅｙｗｏｒｄｓ：ＩｓａｔｉｄｉｓＲａｄｉｘ；ｃｈｅｍｉｃａｌｃｏｍｐｏｓｉｔｉｏｎ；ｈｉｇｈｒｅｓｏｌｕｔｉｏｎｍａｓｓｓｐｅｃｔｒｏｍｅｔｒｙ㊀㊀板蓝根（ＩｓａｔｉｄｉｓＲａｄｉｘ）为十字花科植物菘蓝ＩｓａｔｉｓｉｎｄｉｇｏｔｉｃａＦｏｒｔ．的干燥根㊂菘蓝原产我国，全国各地均有栽培［１］㊂板蓝根为临床常用中药，味苦㊁性寒㊁归心㊁胃经，具有清热解毒，凉血利咽的功效，用于温疫时毒㊁发热咽痛㊁温毒发斑㊁痄腮㊁烂喉丹痧㊁大头瘟疫㊁丹毒㊁痈肿［２］㊂化学成分研究表明，板蓝根主要化学成分有生物碱类㊁有机酸类㊁黄酮类㊁木脂素类㊁蒽醌类㊁甾体类㊁三萜类㊁芥子苷类化合物㊁含硫类化合物㊁氨基酸类等［３－５］㊂现代药理学研究表明，板蓝根具有抗内毒素［６］㊁抗病毒［７］㊁抗肿瘤［８］㊁免疫调节［９］㊁抗炎［１０－１１］和抗氧化［１２］等作用㊂ＵＰＬＣ⁃Ｑ⁃Ｅｘａｃｔｉｖｅ⁃ｏｒｂｉｔｒａｐＭＳ是近几年发展起３１４㊀化㊀学㊀研㊀究２０２３年来的一种新型液相色谱⁃质谱技术，具有分辨率高㊁质量精度好㊁定性㊁定量能力强等特点，也是代谢组学中常用的技术之一，可用于中药原料的定性分析，可实现多种成分的快速鉴定［１３］㊂目前对板蓝根的化学成分研究主要是采用传统的提取分离鉴定方法，耗时比较长，对板蓝根化学成分快速鉴定的研究较少㊂因此，采用ＵＰＬＣ⁃Ｑ⁃Ｅｘａｃｔｉｖｅ⁃ｏｒｂｉ⁃ｔｒａｐＭＳ技术对板蓝根的化学成分进行快速鉴定，为进一步研究板蓝根的药效物质基础和资源利用提供参考㊂１㊀材料和方法１．１㊀仪器㊀㊀旋转蒸发仪（Ｎ⁃１３００，ＥＹＥＬＡ）；电子天平（ＭＥ１０４，ＭＥＴＴＬＥＲＴＯＬＥＤＯ）；超高效液相（Ｗａｔｅｒｓ２ＤＵＰＬＣ，Ｗａｔｅｒｓ，ＵＳＡ）；高分辨质谱（ＱＥｘａｃｔｉｖｅ，ＴｈｅｒｍｏＦｉｓｈｅｒＳｃｉｅｎｔｉｆｉｃ，ＵＳＡ）；色谱柱：ＨｙｐｅｒｓｉｌＧＯＬＤａＱ色谱柱（１００ｍｍˑ２．１ｍｍ，１．９μｍ，ＴｈｅｒｍｏＦｉｓｈｅｒＳｃｉｅｎｔｉｆｉｃ，ＵＳＡ）；低温高速离心机（Ｃｅｎｔｒｉｆｕｇｅ５４３０，Ｅｐｐｅｎｄｏｒｆ）；涡旋仪（ＱＬ⁃９０１，其林贝尔仪器制造有限公司）；纯水仪（Ｍｉｌｌｉ⁃ＱＩｎｔｅｇｒａｌＭｉｌｌｉｐｏｒｅＣｏｒ⁃ｐｏｒａｔｉｏｎＵＳＡ）㊂１．２㊀试剂内标：ｄ３⁃Ｌｅｕｃｉｎｅ，１３Ｃ９⁃Ｐｈｅｎｙｌａｌａｎｉｎｅ，ｄ５⁃Ｔｒｙｐ⁃ｔｏｐｈａｎ，１３Ｃ３⁃Ｐｒｏｇｅｓｔｅｒｏｎｅ；甲醇（Ａ４５４⁃４）㊁乙腈（Ａ９９６⁃４）均为ＬＣＭＳ级别（ＴｈｅｒｍｏＦｉｓｈｅｒＳｃｉｅｎｔｉｆｉｃＵＳＡ）；甲酸（５０１４４⁃５０ｍｌＤＩＭＫＡＵＳＡ）；９５％乙醇（２０１９０３２０，天津市富宇精细化工有限公司）；水由纯水仪提供㊂１．３㊀植物来源板蓝根于２０２２年１２月１８号购买于禹州中药材专业市场㊂１．４㊀样品的制备干燥的板蓝根，粉碎㊂精确称取１００ｇ，加入８００ｍＬ７０％乙醇，回流提取２ｈ，过滤，滤渣加８００ｍＬ７０％乙醇回流提取１ｈ，过滤，合并滤液，浓缩冻干，共得到提取物３０．４ｇ，提取率为３０．４％㊂称取５０ｍｇ提取物，置于１．５ｍＬ离心管中，加入８００μＬ提取液（甲醇ʒ水＝７ʒ３，体积比）和２０μＬ内标，超声３０ｍｉｎ，１４０００ｒ／ｍｉｎ离心１５ｍｉｎ㊂离心后取６００μＬ上清，过０．２２μｍ滤膜后，将过滤后的样本置于上样瓶中等待ＬＣ⁃ＭＳ分析㊂１．５㊀色谱条件所使用的色谱柱为ＨｙｐｅｒｓｉｌＧＯＬＤａＱ色谱柱（１００ｍｍˑ２．１ｍｍ，１．９μｍ，ＴｈｅｒｍｏＦｉｓｈｅｒＳｃｉｅｎｔｉｆｉｃ，ＵＳＡ）㊂流动相为含０．１％甲酸的水溶液（Ａ液）和含０．１％甲酸的乙腈（Ｂ液）㊂采用以下梯度进行洗脱：０ ２ｍｉｎ５％Ｂ液；２ ２２ｍｉｎ５％ ９５％Ｂ液；２２ ２７ｍｉｎ９５％Ｂ液；２７ ３０ｍｉｎ５％Ｂ液㊂流速为０．３ｍＬ／ｍｉｎ，柱温４０ħ，进样量为５μＬ㊂１．６㊀质谱条件利用ＱＥｘａｃｔｉｖｅ质谱仪（ＴｈｅｒｍｏＦｉｓｈｅｒＳｃｉｅｎｔｉｆ⁃ｉｃ，ＵＳＡ）进行一级㊁二级质谱数据采集㊂质谱扫描质荷比范围为１５０ １５００，一级分辨率为７００００，ＡＧＣ为１ｅ６，最大注入时间（ＩＴ，ｉｎｊｅｃｔｉｏｎｔｉｍｅ）为１００ｍｓ㊂按照母离子强度，选择Ｔｏｐ３进行碎裂，采集二级信息，二级分辨率为３５０００，ＡＧＣ为２ｅ５，最大注入时间（ＩＴ，ｉｎｊｅｃｔｉｏｎｔｉｍｅ）为５０ｍｓ，碎裂能量（ｓｔｅｐｐｅｄｎｃｅ）设置为：２０㊁４０和６０ｅＶ㊂离子源（ＥＳＩ）参数设置：鞘气流速（Ｓｈｅａｔｈｇａｓｆｌｏｗｒａｔｅ）为４０，辅助气流速（Ａｕｘｇａｓｆｌｏｗｒａｔｅ）为１０，喷雾电压（Ｓｐｒａｙｖｏｌｔａｇｅ（｜ＫＶ｜）），正离子模式为３．８０，负离子模式为３．２０，离子传输管温度（Ｃａｐｉｌｌａｒｙｔｅｍｐ）为３２０ħ，辅助气加热温度（Ａｕｘｇａｓｈｅａｔｅｒｔｅｍｐ）为３５０ħ㊂１．７㊀数据处理采用ＬＣ⁃ＭＳ／ＭＳ技术对板蓝根进行系统的化学成分分析，将ＬＣ⁃ＭＳ／ＭＳ采集的质谱原始数据导入ＣｏｍｐｏｕｎｄＤｉｓｃｏｖｅｒｅｒ３．３（ＴｈｅｒｍｏＦｉｓｈｅｒＳｃｉ⁃ｅｎｔｉｆｉｃ，ＵＳＡ）进行数据处理，主要包括：峰提取㊁组内及组间的保留时间校正㊁加合离子合并㊁缺失值填充㊁背景峰标记以及代谢物鉴定，最后导出化合物分子量㊁保留时间和鉴定结果等信息㊂化学成分的鉴定结合了ＢＧＩＬｉｂｒａｒｙ（华大自建标准品库）㊁ｍｚＣｌｏｕｄ数据库㊂２㊀结果２．１㊀化学成分鉴定结果㊀㊀采用ＵＰＬＣ⁃Ｑ⁃Ｅｘａｃｔｉｖｅ⁃ｏｒｂｉｔｒａｐＭＳ技术对板蓝根化学成分进行快速鉴定，根据正（ｐｏｓ）负（ｎｅｇ）离子模式下板蓝根样品总离子流图（图１），比对ＢＧＩＬｉｂｒａｒｙ数据库中的保留时间㊁母离子㊁二级碎片离子和ｍｚ⁃Ｃｌｏｕｄ数据库中的母离子㊁二级碎片离子确定化合物㊂从板蓝根中鉴定１１１个化合物，包括１２个氨基酸类㊁１２个苯丙素类㊁２个酚类㊁６个核苷类㊁５个黄酮类㊁１１个生物碱类㊁４个糖类㊁４个萜类㊁７个酰胺类㊁４个香豆素类㊁３３个有机酸类㊁１个甾体类和１０个其他类㊂表１列出了３０种成分的鉴定结果㊂第４期崔维恒等：采用超高效液相色谱⁃四极杆⁃静电场轨道阱高分辨质谱快速鉴定板蓝根的化学成分３１５㊀图１㊀正（ｐｏｓ）负（ｎｅｇ）离子模式下板蓝根样品总离子流图Ｆｉｇ．１㊀ＴｏｔａｌｉｏｎｃｕｒｒｅｎｔｃｈｒｏｍａｔｏｇｒａｍｏｆＩｓａｔｉｄｉｓＲａｄｉｘｉｎｐｏｓｉｔｉｖｅｉｏｎｍｏｄｅ（ｐｏｓ）ａｎｄｎｅｇａｔｉｖｅｉｏｎｍｏｄｅ（ｎｅｇ）表１㊀板蓝根样品的部分化学成分鉴定结果Ｔａｂｌｅ１㊀ＩｄｅｎｔｉｆｉｃａｔｉｏｎｒｅｓｕｌｔｓｏｆｐａｒｔｉａｌｃｈｅｍｉｃａｌｃｏｍｐｏｓｉｔｉｏｎｉｎＩｓａｔｉｄｉｓＲａｄｉｘ序号离子模式保留时间实测值理论值分子式误差／１０－６化合物名称化合物类型１ＰＯＳ０．７３２１７４．１１１９６１７４．１１１６８Ｃ６Ｈ１４Ｎ４Ｏ２１．６３ＤＬ⁃精氨酸氨基酸类２ＰＯＳ１．１５５１８１．０７４２６１８１．０７３８９Ｃ９Ｈ１１ＮＯ３２．０２Ｌ⁃酪氨酸氨基酸类３ＰＯＳ１．３８１３１．０９４８５１３１．０９４６３Ｃ６Ｈ１３ＮＯ２１．６９Ｌ⁃亮氨酸氨基酸类４ＮＥＧ５．２９３５２２．２０９６１５２２．２１０１１Ｃ２６Ｈ３４Ｏ１１－０．９６落叶松树脂醇４－Ｏ葡萄糖苷苯丙素类５ＮＥＧ６．５５８１９４．０５８１９４．０５７９１Ｃ１０Ｈ１０Ｏ４０．４５阿魏酸苯丙素类６ＰＯＳ５．８４１１５２．０４７７１５２．０４７３４Ｃ８Ｈ８Ｏ３２．３５香草醛酚类７ＰＯＳ６．２１９１８２．０５８４４１８２．０５７９１Ｃ９Ｈ１０Ｏ４２．９３３，５⁃二甲氧基⁃４⁃羟基苯甲醛酚类８ＰＯＳ０．８５４２４３．０８５５１２４３．０８５５２Ｃ９Ｈ１３Ｎ３Ｏ５－０．０５胞嘧啶核苷核苷类９ＰＯＳ１．１２６１３５．０５４７５１３５．０５４４９Ｃ５Ｈ５Ｎ５１．８９腺嘌呤核苷类１０ＰＯＳ１．１５６２６７．０９６８８２６７．０９６７５Ｃ１０Ｈ１３Ｎ５Ｏ４０．４７腺苷核苷类１１ＰＯＳ１．１７９２８３．０９１６６２８３．０９１６７Ｃ１０Ｈ１３Ｎ５Ｏ５－０．０４鸟苷核苷类１２ＮＥＧ５．０７８５９４．１５８５８５９４．１５８４７Ｃ２７Ｈ３０Ｏ１５０．１９葡萄糖基芹菜素黄酮类１３ＰＯＳ１０．７２８２６８．０７３５９２６８．０７３５５Ｃ１６Ｈ１２Ｏ４０．１３芒柄花黄素黄酮类１４ＰＯＳ３．００４１２９．０２５２６１２９．０２４８４Ｃ５Ｈ７ＮＯＳ３．２６（Ｒ，Ｓ）⁃告依春生物碱类１５ＰＯＳ６．８６４１６１．０４７５５１６１．０４７６８Ｃ９Ｈ７ＮＯ２－０．８２３⁃吲哚甲酸生物碱类１６ＮＥＧ０．５９１１８０．０６３５３１８０．０６３３９Ｃ６Ｈ１２Ｏ６０．７６Ｌ⁃山梨糖糖类１７ＰＯＳ１．０５７５０４．１７００１５０４．１６９０３Ｃ１８Ｈ３２Ｏ１６１．９４松三糖糖类１８ＮＥＧ４．５１７３５６．１１０７６３５６．１１０７３Ｃ１６Ｈ２０Ｏ９０．０７龙胆苦苷萜类１９ＰＯＳ１８．８８４４５６．３６０８５４５６．３６０３４Ｃ３０Ｈ４８Ｏ３１．１１熊果酸萜类２０ＰＯＳ１２．６１１１７１．１６２５１１７１．１６２３１Ｃ１０Ｈ２１ＮＯ１．１５癸酰胺酰胺类２１ＰＯＳ２２．３７９３３９．３４９８７３３９．３５０１１Ｃ２２Ｈ４５ＮＯ－０．７２二十二酰胺酰胺类２２ＰＯＳ１３．９４５３００．０９９６１３００．０９９７８Ｃ１７Ｈ１６Ｏ５－０．５６珊瑚菜内脂香豆素类２３ＰＯＳ１４．７０６２４４．１０９８２４４．１０９９４Ｃ１５Ｈ１６Ｏ３－０．５７软木花椒素香豆素类２４ＮＥＧ０．８３２１３４．０２１５６１３４．０２１５２Ｃ４Ｈ６Ｏ５０．２７ＤＬ⁃苹果酸有机酸类２５ＮＥＧ１０．７４５２３０．１５１５６２３０．１５１８Ｃ１２Ｈ２２Ｏ４－１．０６十二烷二酸有机酸类２６ＮＥＧ７．４２４１８８．１０５１８８．１０４８６Ｃ９Ｈ１６Ｏ４０．７６壬二酸有机酸类２７ＰＯＳ１０．７２２７２．１７７６３２７２．１７７６３Ｃ１８Ｈ２４Ｏ２０．０２１９⁃去甲⁃４⁃雄烯二酮甾体类２８ＰＯＳ１４．４５５３５６．２９２２５３５６．２９２６６Ｃ２１Ｈ４０Ｏ４－１．１５油酸单甘油酯其他类２９ＰＯＳ１．０３７１２６．０３１８９１２６．０３１７Ｃ６Ｈ６Ｏ３１．５２５⁃羟甲基⁃２⁃呋喃醛其他类３０ＰＯＳ１６．５９７２９９．２８２２１２９９．２８２４３Ｃ１８Ｈ３７ＮＯ２－０．７２Ｄ⁃鞘氨醇其他类２．２㊀部分化合物质谱裂解规律分析２．２．１㊀氨基酸类化合物质谱裂解规律分析㊀㊀氨基酸类化合物裂解一般容易得到ＮＨ３㊁ＨＣＯＯＨ㊁Ｈ２Ｏ㊁ＣＯ２和ＣＯ等基团的碎片［１４－１５］㊂以化合物１（ＤＬ⁃精氨酸）为例，在正离子模式下响应，质子化得到准分子离子ｍ／ｚ１７５［Ｍ＋Ｈ］＋，然后失去一分子ＮＨ３得到离子碎片ｍ／ｚ１５８［Ｍ＋Ｈ－ＮＨ３］＋，进一步失去ＣＯ基团得到离子碎片ｍ／ｚ１３０［Ｍ＋Ｈ－ＮＨ３－ＣＯ］＋㊂同时，准分子３１６㊀化㊀学㊀研㊀究２０２３年离子也可以失去ＣＨ５Ｎ３和Ｃ５Ｈ９ＮＯ２基团分别得到ｍ／ｚ１１６［Ｍ＋Ｈ－ＣＨ５Ｎ３］＋和ｍ／ｚ６０［Ｍ＋Ｈ－Ｃ５Ｈ９ＮＯ２］＋两个离子碎片㊂离子碎片ｍ／ｚ１１６［Ｍ＋Ｈ－ＣＨ５Ｎ３］＋进一步失去ＨＣＯＯＨ得到碎片ｍ／ｚ７０［Ｍ＋Ｈ－ＣＨ５Ｎ３－ＨＣＯＯＨ］＋㊂ＤＬ⁃精氨酸可能的裂解途径见图２㊂图２㊀ＤＬ⁃精氨酸可能的裂解途径Ｆｉｇ．２㊀ＰｏｓｓｉｂｌｅｃｌｅａｖａｇｅｐａｔｈｗａｙｏｆＤＬ⁃ａｒｇｉｎｉｎｅ２．２．２㊀苯丙素类化合物裂解规律分析以化合物５为例，在负离子模式下响应去质子化得到准分子离子ｍ／ｚ１９３［Ｍ－Ｈ］－，然后失去ＣＨ３基团得到碎片离子ｍ／ｚ１７８［Ｍ－Ｈ－ＣＨ３］－，进一步失去ＣＯ２基团得到碎片离子ｍ／ｚ１３４［Ｍ－Ｈ－ＣＨ３－ＣＯ２］－㊂结合文献报道［１６］推测化合物５可能为阿魏酸㊂可能的裂解途径见图３㊂图３㊀阿魏酸可能的裂解途径Ｆｉｇ．３㊀Ｐｏｓｓｉｂｌｅｃｌｅａｖａｇｅｐａｔｈｗａｙｓｏｆｆｅｒｕｌｉｃａｃｉｄ２．２．３㊀核苷类化合物裂解规律分析核苷类化合物由一分子碱和一分子核糖组成，一般容易在正离子模式下响应得到准分子离子［Ｍ＋Ｈ］＋，然后得到失去一分子核糖的碎片离子［１５］㊂以化合物１０为例，在正离子模式下得到准分子离子ｍ／ｚ２６８［Ｍ＋Ｈ］＋，然后失去一分子核糖得到碎片离子ｍ／ｚ１３６［Ｍ＋Ｈ－Ｃ５Ｈ８Ｏ４］＋㊂推测化合物１０可能为腺苷，可能的裂解途径见图４㊂图４㊀腺苷可能的裂解途径Ｆｉｇ．４㊀Ｐｏｓｓｉｂｌｅｐａｔｈｗａｙｓｆｏｒａｄｅｎｏｓｉｎｅｃｌｅａｖａｇｅ２．２．４㊀生物碱类化合物裂解规律分析以化合物１４为例，在正离子模式下响应，质子化得到准分子离子ｍ／ｚ１３０［Ｍ＋Ｈ］＋，然后失去ＣＯＳ基团，得到二级碎片离子ｍ／ｚ７０［Ｍ＋Ｈ－ＣＯＳ］＋，推测化合物１４可能为（Ｒ，Ｓ）⁃告依春，可能的裂解途径见图５㊂图５㊀（Ｒ，Ｓ）⁃告依春可能的裂解途径Ｆｉｇ．５㊀Ｐｏｓｓｉｂｌｅｃｌｅａｖａｇｅｐａｔｈｗａｙｓｏｆ（Ｒ，Ｓ）⁃ｓｐｒｉｎｇ２．２．５㊀有机酸类化合物裂解规律分析有机酸类化合物一般在负离子模式下响应，容易得到失去Ｈ２Ｏ㊁ＣＯ㊁ＣＯ２等基团的碎片离子［１５］㊂第４期崔维恒等：采用超高效液相色谱⁃四极杆⁃静电场轨道阱高分辨质谱快速鉴定板蓝根的化学成分３１７㊀以化合物２６为例，在负离子模式下响应得到准分子离子ｍ／ｚ１８７［Ｍ－Ｈ］－，然后失去一分子Ｈ２Ｏ，得到碎片离子ｍ／ｚ１６９［Ｍ－Ｈ－Ｈ２Ｏ］－，进一步失去ＣＯ２基团得到碎片离子ｍ／ｚ１２５［Ｍ－Ｈ－Ｈ２Ｏ］－，结合文献报道［１７］推测化合物２６可能为壬二酸㊂３㊀讨论采用ＵＰＬＣ⁃Ｑ⁃Ｅｘａｃｔｉｖｅ⁃ｏｒｂｉｔｒａｐＭＳ技术对板蓝根的化学成分进行快速鉴定，板蓝根化学成分主要包括氨基酸类㊁苯丙素类㊁核苷类㊁黄酮类㊁生物碱类㊁香豆素类和有机酸类等㊂文献研究表明生物碱类㊁有机酸类㊁苯丙素类㊁多肽类㊁多糖类等为板蓝根的主要抗病毒活性成分［１８－１９］㊂其中生物碱类成分是板蓝根的标志性成分，主要类型有吲哚类㊁喹唑啉酮类㊁喹啉和异喹啉类㊁其他杂环类㊁苯胺类㊁酰胺类等，以吲哚类生物碱为主，代表性成分有靛蓝和靛玉红［４，２０］，现行药典‘中国药典“２０２０年版一部规定含硫类生物碱（Ｒ，Ｓ）⁃告依春作为质量控制成分，规定含量不得低于０．０２０％［２］㊂也有文献将木脂素类化合物和核苷类化合物作为板蓝根的质控成分［２１］㊂上述几类成分在本研究中均检测到㊂采用ＵＰＬＣ⁃Ｑ⁃Ｅｘａｃｔｉｖｅ⁃ｏｒｂｉｔｒａｐＭＳ技术快速地从板蓝根中共鉴定１１１个化合物，从成分含量的角度分析发现，核苷类的腺嘌呤㊁香豆素类的软木花椒素㊁氨基酸类的ＤＬ⁃精氨酸㊁Ｌ⁃亮氨酸以及有机酸类ＤＬ⁃苹果酸和对氨基苯甲酸含量最多，为板蓝根的主要含量元素；除此之外，一些常量元素如核苷类的腺苷和胞嘧啶核苷以及生物碱类的（Ｒ，Ｓ）⁃告依春也较多地存在，还包含一些微量元素如生物碱类的３⁃吲哚甲酸和有机酸类的十二烷二酸等㊂这些发现为板蓝根成分含量提供了数据支撑，也为板蓝根的质量研究提供了参考㊂以上多数化学成分均有报道从板蓝根中分离鉴定过㊂相比传统提取分离方法，该方法较为高效㊁准确㊂本研究为板蓝根在体内的物质基础分析，尤其是微量成分的体内代谢研究提供了方法借鉴㊂４㊀结论本研究利用ＵＰＬＣ⁃Ｑ⁃Ｅｘａｃｔｉｖｅ⁃ｏｒｂｉｔｒａｐＭＳ技术的分辨率高㊁灵敏度高等特点鉴定了板蓝根中１１１个化合物，包括１２个氨基酸类㊁１２个苯丙素类㊁２个酚类㊁６个核苷类㊁５个黄酮类㊁１１个生物碱类㊁４个糖类㊁４个萜类㊁７个酰胺类㊁４个香豆素类㊁３３个有机酸类㊁１个甾体类和１０个其他类㊂对部分化合物质谱裂解规律分析；同时进一步对其常量元素㊁少量元素和微量元素展开初步讨论分析，为进一步研究板蓝根的药效物质基础和资源利用提供参考与借鉴㊂参考文献：［１］中国科学院‘中国植物志“编委会．中国植物志［Ｍ］．北京：科学出版社，１９８７，３３：６５．ＥｄｉｔｏｒｉａｌＢｏａｒｄｏｆＦｌｏｒａｏｆＣｈｉｎａ，ＣｈｉｎｅｓｅＡｃａｄｅｍｙｏｆＳｃｉｅｎｃｅｓ．ＦｌｏｒａｏｆＣｈｉｎａ［Ｍ］．Ｂｅｉｊｎｇ：ＳｃｉｅｎｃｅＰｒｅｓｓ，１９８７，３３：６５．［２］国家药典委员会．中华人民共和国药典－一部［Ｍ］．北京：中国医药科技出版社，２０２０：２１４⁃２１５．ＮａｔｉｏｎａｌＰｈａｒｍａｃｏｐｏｅｉａＣｏｍｍｉｓｓｉｏｎ．ＰｈａｒｍａｃｏｐｏｅｉａｏｆｔｈｅＰｅｏｐｌｅ ｓＲｅｐｕｂｌｉｃｏｆＣｈｉｎａ Ｐａｒｔ１［Ｍ］．Ｂｅｉｊｉｎｇ：ＣｈｉｎａＭｅｄｉｃａｌＳｃｉｅｎｃｅａｎｄＴｅｃｈｎｏｌｏｇｙＰｒｅｓｓ，２０２０：２１４⁃２１５．［３］彭少平，顾振纶．板蓝根化学成分㊁药理作用研究进展［Ｊ］．中国野生植物资源，２００５，２４（５）：４⁃７．ＰＥＮＧＳＰ，ＧＵＺＧ．ＲｅｃｅｎｔｐｒｏｇｒｅｓｓｉｎｔｈｅｓｔｕｄｉｅｓｏｆｃｈｅｍｉｃａｌｃｏｎｓｔｉｔｕｅｎｔｓａｎｄｐｈａｒｍａｃｏｌｏｇｉｃａｌｅｆｆｅｃｔｓｏｎＲｏｏｔｓｏｆＩｓａｔｉｓｉｎｄｉｇｏｔｉｃａ［Ｊ］．ＣｈｉｎｅｓｅＷｉｌｄＰｌａｎｔＲｅｓｏｕｒｃｅｓ，２００５，２４（５）：４⁃７．［４］武佳，解云霞．板蓝根化学成分及质量控制研究［Ｊ］．时珍国医国药，２００６，１７（１０）：２０６７⁃２０６８．ＷＵＪ，ＸＩＥＹＸ．ＴｈｅｓｔｕｄｉｅｓｏｆｃｈｅｍｉｃａｌｉｎｇｒｅｄｉｅｎｔｓａｎｄｑｕａｌｉｔｙｃｏｎｔｒｏｌｍｅｔｈｏｄｓｏｎｔｈｅＲｏｏｔｓｏｆｉｓａｔｉｓｉｎｄｉｇｏｔｉｃａ［Ｊ］．ＬｉｓｈｉｚｈｅｎＭｅｄｉｃｉｎｅａｎｄＭａｔｅｒｉａＭｅｄｉｃａＲｅｓｅａｒｃｈ，２００６，１７（１０）：２０６７⁃２０６８．［５］施霞，倪华，刘云海．板蓝根化学成分及其药理活性研究进展［Ｊ］．中国医院药学杂志，２００６，２６（１１）：１３９７⁃１３９９．ＳＨＩＸ，ＮＩＨ，ＬＩＵＹＨ．ＲｅｓｅａｒｃｈｐｒｏｇｒｅｓｓｏｎｃｈｅｍｉｃａｌｃｏｎｓｔｉｔｕｅｎｔｓａｎｄｐｈａｒｍａｃｏｌｏｇｉｃａｌａｃｔｉｖｉｔｉｅｓｏｆＲａｄｉｘＩｓａｔｉｄｉｓ［Ｊ］．ＣｈｉｎｅｓｅＪｏｕｒｎａｌｏｆＨｏｓｐｉｔａｌＰｈａｒｍａｃｙ，２００６，２６（１１）：１３９７⁃１３９９．［６］刘云海，林爱华，丁水平，等．板蓝根对内毒素致炎性因子的影响［Ｊ］．中国药科大学学报，２００１，３２（２）：１４９⁃１５１．ＬＩＵＹＨ，ＬＩＮＡＨ，ＤＩＮＧＳＰ，ｅｔａｌ．ＥｆｆｅｃｔｓｏｆＲａｄｉｘＩｓａｔｉｄｉｓｏｎｔｈｅｐｒｏｄｕｃｔｉｏｎｏｆＴＮＦαａｎｄＩＬ⁃６ｉｎｍａｃｒｏｐｈａｇｅｆｒｏｍｍｉｃｅｉｎｄｕｃｅｄｂｙｅｎｄｏｔｏｘｉｎ［Ｊ］．ＪｏｕｒｎａｌｏｆＣｈｉｎａＰｈａｒｍａｃｅｕｔｉｃａｌＵｎｉｖｅｒｓｉｔｙ，２００１，３２（２）：１４９⁃１５１．［７］徐丽华，黄芳，陈婷，等．板蓝根中的抗病毒活性成分［Ｊ］．中国天然药物，２００５，３（６）：３５９⁃３６０．ＸＵＬＨ，ＨＵＡＮＧＦ，ＣＨＥＮＴ，ｅｔａｌ．ＡｎｔｉｖｉｒｕｓＣｏｎｓｔｉｔｕｅｎｔｓｏｆＲａｄｉｘｏｆＩｓａｔｉｓｉｎｄｉｇｏｔｉｃａ［Ｊ］．ＣｈｉｎｅｓｅＪｏｕｒｎａｌｏｆＮａｔｕｒａｌＭｅｄｉｃｉｎｅｓ，２００５，３（６）：３５９⁃３６０．［８］侯华新，黎丹戎，秦箐，等．板蓝根高级不饱和脂肪组酸体内抗肿瘤实验研究［Ｊ］．中国新药与临床药理，３１８㊀化㊀学㊀研㊀究２０２３年２００２，１３（３）：１５６⁃１５７．ＨＯＵＨＸ，ＬＩＤＲ，ＱＩＮＱ，ｅｔａｌ．ＡｎＥｘｐｅｒｉｍｅｎｔａｌｓｔｕｄｙｏｎｉｎ⁃ｖｉｖｏａｎｔｉｔｕｍｏｒａｃｔｉｏｎｏｆｈｉｇｈｅｒｕｎｓａｔｕｒａｔｅｄｆａｔｔｙａｃｉｄｓｆｏｒｍＲａｄｉｘＩｓａｔｉｄｉｓ［Ｊ］．ＴｒａｄｉｔｉｏｎａｌＣｈｉｎｅｓｅＤｒｕｇＲｅｓｅａｒｃｈａｎｄＣｌｉｎｉｃａｌＰｈａｒｍａｃｏｌｏｇｙ，２００２，１３（３）：１５６⁃１５７．［９］ＴＡＯＷ，ＦＵＴ，ＨＥＺＪ，ｅｔａｌ．ＩｍｍｕｎｏｍｏｄｕｌａｔｏｒｙｅｆｆｅｃｔｓｏｆＲａｄｉｘｉｓａｔｉｄｉｓｐｏｌｙｓａｃｃｈａｒｉｄｅｓｉｎｖｉｔｒｏａｎｄｉｎｖｉｖｏ［Ｊ］．ＥｘｐｅｒｉｍｅｎｔａｌａｎｄＴｈｅｒａｐｅｕｔｉｃＭｅｄｉｃｉｎｅ，２０２１，２２（６）：１４０５．［１０］ＲＥＮＬＴ，ＬＩＱ，ＬＩＨ，ｅｔａｌ．ＰｏｌｙｓａｃｃｈａｒｉｄｅｅｘｔｒａｃｔｆｒｏｍＩｓａｔｉｄｉｓＲａｄｉｘｉｎｈｉｂｉｔｓｍｕｌｔｉｐｌｅｉｎｆｌａｍｍａｓｏｍｅｓａｃｔｉｖａｔｉｏｎａｎｄａｌｌｅｖｉａｔｅｇｏｕｔｙａｒｔｈｒｉｔｉｓ［Ｊ］．ＰｈｙｔｏｔｈｅｒａｐｙＲｅｓｅａｒｃｈ，２０２２，３６（８）：３２９５⁃３３１２．［１１］马毅敏，李娜，刘承伟，等．板蓝根不同提取部位抗炎镇痛活性比较研究［Ｊ］．中草药，２０１４，４５（１７）：２５１７⁃２５２１．ＭＡＹＭ，ＬＩＮ，ＬＩＵＣＷ，ｅｔａｌ．Ｃｏｍｐａｒａｔｉｖｅｓｔｕｄｉｅｓｏｎａｎｔｉ⁃ｉｎｆｌａｍｍａｔｏｒｙａｎｄａｎａｌｇｅｓｉｃａｃｔｉｖｉｔｉｅｓｏｆｄｉｆｆｅｒｅｎｔｆｒａｃｔｉｏｎｓｆｒｏｍＩｓａｔｉｄｉｓＲａｄｉｘ［Ｊ］．ＣｈｉｎｅｓｅＨｅｒｂａｌＭｅｄｉｃｉｎｅｓ，２０１４，４５（１７）：２５１７⁃２５２１．［１２］闫峻，赵春芳，李伯平，等．板蓝根化学成分及抗氧化活性的研究［Ｊ］．质谱学报，２０１７，３８（２）：２４８⁃２５５．ＹＡＮＪ，ＺＨＡＯＣＦ，ＬＩＢＰ，ｅｔａｌ．ＣｈｅｍｉｃａｌｃｏｎｓｔｉｔｕｅｎｔｓａｎｄａｎｔｉｏｘｉｄａｎｔａｃｔｉｖｉｔｙｏｆＲａｄｉｘＩｓａｔｉｄｉｓ［Ｊ］．ＪｏｕｒｎａｌｏｆＣｈｉｎｅｓｅＭａｓｓＳｐｅｃｔｒｏｍｅｔｒｙＳｏｃｉｅｔｙ，２０１７，３８（２）：２４８⁃２５５．［１３］曾彬，刘红梅，刘晓梅，等．ＵＰＬＣ⁃Ｑ⁃ＥｘａｃｔｉｖｅＯｒｂｉｔｒａｐＭＳ技术在中药分析中的应用［Ｊ］．中药材，２０２０，４３（９）：２３１３⁃２３１９．ＺＥＮＧＢ，ＬＩＵＨＭ，ＬＩＵＸＭ，ｅｔａｌ．ＡｐｐｌｉｃａｔｉｏｎｏｆＵＰＬＣ⁃Ｑ⁃ＥｘａｃｔｉｖｅＯｒｂｉｔｒａｐＭＳｔｅｃｈｎｉｑｕｅｉｎｔｈｅａｎａｌｙｓｉｓｏｆｔｒａｄｉｔｉｏｎａｌＣｈｉｎｅｓｅｍｅｄｉｃｉｎｅ［Ｊ］．ＪｏｕｒｎａｌｏｆＣｈｉｎｅｓｅＭｅｄｉｃｉｎａｌＭａｔｅｒｉａｌｓ，２０２０，４３（９）：２３１３⁃２３１９．［１４］蒋希羽，庄楷，张雅净，等．基于ＵＰＬＣ⁃Ｑ⁃Ｅｘａｃｔｉｖｅ⁃Ｏｒｂｉｔｒａｐ⁃ＭＳ的桂枝茯苓丸化学成分分析［Ｊ］．中药材，２０２１，４４（８）：１８８９⁃１８９４．ＪＩＡＮＧＸＹ，ＺＨＵＡＮＧＫ，ＺＨＡＮＧＹＪ，ｅｔａｌ．ＣｈｅｍｉｃａｌｃｏｍｐｏｓｉｔｉｏｎａｎａｌｙｓｉｓｏｆＧｕｉｚｈｉＰｏｒｉａＰｉｌｌｓｂａｓｅｄｏｎＵＰＬＣ⁃Ｑ⁃Ｅｘａｃｔｉｖｅ⁃Ｏｒｂｉｔｒａｐ⁃ＭＳ［Ｊ］．ＪｏｕｒｎａｌｏｆＣｈｉｎｅｓｅＭｅｄｉｃｉｎａｌＭａｔｅｒｉａｌｓ，２０２１，４４（８）：１８８９⁃１８９４．［１５］ＣＵＩＬＬ，ＬＩＵＹＨ，ＬＩＵＭ，ｅｔａｌ．ＩｄｅｎｔｉｆｉｃａｔｉｏｎｏｆｐｈｙｔｏｃｈｅｍｉｃａｌｓｆｒｏｍＬｅｎｔｉｎｕｓｅｄｏｄｅｓａｎｄａｕｒｉｃｕｌａｒｉａａｕｒｉｃｕｌａｗｉｔｈＵＰＬＣ⁃Ｑ⁃ｅｘａｃｔｉｖｅｏｒｂｉｔｒａｐＭＳ［Ｊ］．ＪｏｕｒｎａｌｏｆＦｕｔｕｒｅＦｏｏｄｓ，２０２２，２（３）：２５３⁃２６０．［１６］崔小敏，万兆新，任慧，等．基于ＵＰＬＣ⁃Ｑ⁃ＯｒｂｉｔｒａｐＨＲＭＳ技术的白毛银露梅化学成分研究［Ｊ］．中药材，２０２０，４３（８）：１９０１⁃１９０６．ＣＵＩＸＭ，ＷＡＮＺＸ，ＲＥＮＨ，ｅｔａｌ．Ｃｈｅｍｉｃａｌｃｏｎｓｔｉｔｕｅｎｔｓｏｆｐｏｔｅｎｔｉｌｌａｇｌａｂｒａｖａｒ．ｍａｎｄｓｈｕｒｉｃａｂａｓｅｄｏｎＵＰＬＣ⁃Ｑ⁃ＯｒｂｉｔｒａｐＨＲＭＳ［Ｊ］．ＪｏｕｒｎａｌｏｆＣｈｉｎｅｓｅＭｅｄｉｃｉｎａｌＭａｔｅｒｉａｌｓ，２０２０，４３（８）：１９０１⁃１９０６．［１７］安太勇，陈晓虎，张梅，等．ＵＰＬＣ⁃Ｑ⁃Ｅｘａｃｔｉｖｅ四极杆⁃静电场轨道阱高分辨质谱联用快速分析川党参的化学成分［Ｊ］．中草药，２０１８，４９（７）：１５３３⁃１５４２．ＡＮＴＹ，ＣＨＥＮＸＨ，ＺＨＡＮＧＭ，ｅｔａｌ．ＲａｐｉｄａｎａｌｙｓｉｓｏｎｃｈｅｍｉｃａｌｃｏｎｓｔｉｔｕｅｎｔｓｉｎｒｏｏｔｓｏｆｃｏｄｏｎｏｐｓｉｓｔａｎｇｓｈｅｎｂｙＵＰＬＣｃｏｕｐｌｅｄｗｉｔｈＱ⁃ｅｘａｃｔｉｖｅｑｕａｄｒｕｐｏｌｅ⁃ｏｒｂｉｔｒａｐｍａｓｓｓｐｅｃｔｒｏｍｅｔｒｙ［Ｊ］．ＣｈｉｎｅｓｅＴｒａｄｉｔｉｏｎａｌａｎｄＨｅｒｂａｌＤｒｕｇｓ，２０１８，４９（７）：１５３３⁃１５４２．［１８］邓九零，陶玉龙，何玉琼，等．板蓝根抗流感病毒活性成分及其作用机制研究进展［Ｊ］．中国中药杂志，２０２１，４６（８）：２０２９⁃２０３６．ＤＥＮＧＪＬ，ＴＡＯＹＬ，ＨＥＹＱ，ｅｔａｌ．ＲｅｓｅａｒｃｈｐｒｏｇｒｅｓｓｏｎａｃｔｉｖｅｃｏｍｐｏｎｅｎｔｓａｎｄｍｅｃｈａｎｉｓｍｏｆＩｓａｔｉｄｉｓＲａｄｉｘｆｏｒｉｎｆｌｕｅｎｚａｖｉｒｕｓ［Ｊ］．ＣｈｉｎａＪｏｕｒｎａｌｏｆＣｈｉｎｅｓｅＭａｔｅｒｉａＭｅｄｉｃａ，２０２１，４６（８）：２０２９⁃２０３６．［１９］杨建昕，李峰，李娜，等．板蓝根抗病毒活性成分研究进展［Ｊ］．辽宁中医药大学学报，２０１６，１８（７）：１４１⁃１４３．ＹＡＮＧＪＸ，ＬＩＦ，ＬＩＮ，ｅｔａｌ．ＲｅｓｅａｒｃｈｐｒｏｇｒｅｓｓｏｆａｎｔｉｖｉｒａｌａｃｔｉｖｅｉｎｇｒｅｄｉｅｎｔｓｏｆＩｓａｔｉｄｉｓＲａｄｉｘ［Ｊ］．ＪｏｕｒｎａｌｏｆＬｉａｏｎｉｎｇＵｎｉｖｅｒｓｉｔｙｏｆＴｒａｄｉｔｉｏｎａｌＣｈｉｎｅｓｅＭｅｄｉｃｉｎｅ，２０１６，１８（７）：１４１⁃１４３．［２０］聂黎行，王馨平，黄烈岩，等．板蓝根化学成分信息库的构建［Ｊ］．中国药学杂志，２０２２，５７（６）：４２８⁃４５２．ＮＩＥＬＨ，ＷＡＮＧＸＰ，ＨＵＡＮＧＬＹ，ｅｔａｌ．ＣｏｎｓｔｒｕｃｔｉｏｎｏｆｉｎｆｏｒｍａｔｉｏｎｂａｎｋｏｆｃｈｅｍｉｃａｌｃｏｍｐｏｎｅｎｔｓｉｎＩｓａｔｉｄｉｓＲａｄｉｘ［Ｊ］．ＣｈｉｎｅｓｅＰｈａｒｍａｃｅｕｔｉｃａｌＪｏｕｒｎａｌ，２０２２，５７（６）：４２８⁃４５２．［２１］黄远，董福越，李楚源，等．一测多评法测定板蓝根中６种化学成分的含量［Ｊ］．中草药，２０２１，５２（３）：８４５⁃８５１．ＨＵＡＮＧＹ，ＤＯＮＧＦＹ，ＬＩＣＹ，ｅｔａｌ．Ｓｉｍｕｌｔａｎｅｏｕｓｑｕａｎｔｉｔａｔｉｖｅｄｅｔｅｒｍｉｎａｔｉｏｎｏｆ１０ｃｈｅｍｉｃａｌｃｏｎｓｔｉｔｕｅｎｔｓｉｎＲａｄｉｘＩｓａｔｉｄｉｓｂｙＱＡＭＳｍｅｔｈｏｄ［Ｊ］．ＣｈｉｎｅｓｅＨｅｒｂａｌＭｅｄｉｃｉｎｅｓ，２０２１，５２（３）：８４５⁃８５１．［责任编辑：郭续更］。